EVA: Evista Alendronate Comparison

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Alendronate; Raloxifene Hydrochloride

Criteria

Inclusion Criteria

• 50-80 years of age, inclusive

• 2 years since last menses

• Dx femoral neck osteoporosis

• No vertebral fractures

Exclusion Criteria

• Poor candidate for study drugs

• Hx of diseases affecting bone metabolism

• Hx of breast/estrogen-dependent cancer

• Current use of osteoporosis drug therapy

• Hx/high risk of VTE